Brief description of study

Detailed Study Description

This is a multicentre, randomized, double-blind, placebo controlled, parallel group study
designed to evaluate the efficacy and safety of tezepelumab in adults and adolescents with
severe, uncontrolled asthma on medium to high-dose ICS and at least one additional asthma
controller medication with or without OCS. Approximately 1060 subjects will be randomized
globally. Subjects will receive tezepelumab, or placebo, administered via subcutaneous
injection at the study site, over a 52-week treatment period. The study also includes a
post-treatment follow-up period of 12 weeks.